Press Releases April 24, 2026 06:00 PM

BlackRock® Canada Announces Final April Cash Distributions for the iShares® Premium Money Market ETF

BlackRock Canada declares final April 2026 cash distribution for iShares Premium Money Market ETF

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
CMR

BlackRock Asset Management Canada Limited, a subsidiary of BlackRock, Inc., announced the final cash distribution for April 2026 for the iShares Premium Money Market ETF (ticker: CMR). Unitholders of record as of April 27, 2026, will receive cash distributions of $0.102 per unit on April 30, 2026.

BlackRock® Canada Announces Final April Cash Distributions for the iShares® Premium Money Market ETF
CMR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • BlackRock Canada announced the final April 2026 cash distribution for the iShares Premium Money Market ETF.
  • The distribution amount is $0.102 per unit with payment scheduled for April 30, 2026.
  • iShares ETFs are managed by BlackRock Canada and represent a large portion of BlackRock's assets under management at approximately $5.5 trillion globally as of March 31, 2026.

TORONTO, April 24, 2026 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the final April 2026 cash distributions for the iShares Premium Money Market ETF. Unitholders of record on April 27, 2026 will receive cash distributions payable on April 30, 2026.

Details regarding the final “per unit” distribution amounts are as follows:

Fund NameFund
Ticker
Cash
Distribution
Per Unit
iShares Premium Money Market ETFCMR$0.102


Further information on the iShares ETFs can be found at http://www.blackrock.com/ca.

About BlackRock
BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate.

About iShares ETFs
iShares unlocks opportunity across markets to meet the evolving needs of investors. With more than twenty years of experience, a global line-up of more than 1,700 exchange traded funds (ETFs) and approximately $5.5 trillion in assets under management as of March 31, 2026, iShares continues to drive progress for the financial industry. iShares funds are powered by the expert portfolio and risk management of BlackRock.   

iShares® ETFs are managed by BlackRock Canada.

Commissions, trailing commissions, management fees and expenses all may be associated with investing in iShares ETFs. Please read the relevant prospectus before investing. The funds are not guaranteed, their values change frequently and past performance may not be repeated. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional.

Contact for Media:
Sydney Punchard
Email: Sydney.Punchard@blackrock.com


Risks

  • Values of iShares ETFs, including the Premium Money Market ETF, fluctuate frequently and past performance is not indicative of future results.
  • Investing in these ETFs involves management fees, commissions, and expenses which can impact overall returns.
  • Market conditions and interest rate changes can affect money market fund yields and distributions.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026